William Blair Investment Management LLC Has $169.62 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)

William Blair Investment Management LLC increased its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 16.1% during the fourth quarter, Holdings Channel reports. The fund owned 1,944,695 shares of the biotechnology company’s stock after acquiring an additional 269,896 shares during the quarter. William Blair Investment Management LLC’s holdings in Blueprint Medicines were worth $169,616,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in BPMC. Empirical Asset Management LLC bought a new stake in shares of Blueprint Medicines during the 4th quarter valued at $2,348,000. Stephens Inc. AR bought a new stake in shares of Blueprint Medicines during the 4th quarter valued at $321,000. Massachusetts Financial Services Co. MA lifted its position in shares of Blueprint Medicines by 48.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after acquiring an additional 82,693 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Blueprint Medicines by 2.4% during the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company’s stock valued at $26,465,000 after acquiring an additional 7,101 shares during the period. Finally, KBC Group NV lifted its position in shares of Blueprint Medicines by 63.9% during the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 1,023 shares during the period.

Analysts Set New Price Targets

Several analysts recently weighed in on BPMC shares. Stephens restated an “overweight” rating and set a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. StockNews.com cut Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. Wedbush restated an “outperform” rating and set a $128.00 target price on shares of Blueprint Medicines in a research report on Friday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and set a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $125.21.

Insider Buying and Selling at Blueprint Medicines

In other news, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $95.91, for a total value of $218,099.34. Following the completion of the transaction, the chief operating officer now directly owns 69,383 shares in the company, valued at approximately $6,654,523.53. This represents a 3.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ariel Hurley sold 2,250 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the transaction, the insider now owns 14,967 shares of the company’s stock, valued at $1,496,700. This trade represents a 13.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,608 shares of company stock valued at $4,668,161 over the last quarter. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Price Performance

Shares of BPMC opened at $89.58 on Monday. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90. The firm’s fifty day simple moving average is $99.54 and its 200-day simple moving average is $94.04. The firm has a market capitalization of $5.72 billion, a price-to-earnings ratio of -82.94 and a beta of 0.58. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Equities analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.